Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10240139 | 0.86 | RET (0.36) | METMTORRPTORMLST8ALOX5AP | |
| SCHEMBL10240142 | 0.85 | MTOR (0.43) | MAPK1METMTORRPTORMLST8 | |
| SCHEMBL10240062 | 0.85 | TMEM97 (0.34) | METMTORRPTORMLST8CHEK1 | |
| SCHEMBL10240063 | 0.83 | MTOR (0.35) | METMTORRPTORMLST8CHEK1 | |
| SCHEMBL10240064 | 0.83 | MET (0.33) | METMTORRPTORMLST8CHEK1 | |
| SCHEMBL10240036 | 0.82 | KDM4E (0.36) | METMTORRPTORMLST8CHEK1 | |
| SCHEMBL10240057 | 0.82 | GRM5 (0.39) | METMTORRPTORMLST8CHEK1 | |
| SCHEMBL10240055 | 0.81 | MET (0.34) | METMTORRPTORMLST8CHEK1 | |
| SCHEMBL10280309 | 0.80 | FEN1 (0.41) | MAPK1METMTORRPTORMLST8 | |
| SCHEMBL10234953 | 0.80 | GPR119 (0.36) | MAPK1GPR119METMTORRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MAPK1 277/4885GPR119 807/4885MET 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.